Frank Manning

Director of Sales Development at Speridian Technologies

[Frank Manning @fmanning16]

RQMIS's latest blog on Cybersecurity in Medical Devices with a focus on Postmarket Surveillance in your 510(k)/DeNovo/PMA submission. https://t.co/5oy0jkwHKh

[Frank Manning @fmanning16]

Click on the link below to learn about our Cybersecurity in Medical Devices service.

https://t.co/DXsmnLg1nk https://t.co/src8UHqP7D

[Frank Manning @fmanning16]

https://t.co/4aMmtkT76a https://t.co/cmAqN8Xt3g

[Frank Manning @fmanning16]

RQMIS, Inc. and Twin Tech Labs are pleased to announce a new partnership to bring cybersecurity testing and monitoring to the ever-expanding market of software-based medical products and their associated network and cloud-based platforms.

Contact me at f…https://t.co/sViE5dGHqU

[Frank Manning @fmanning16]

Does Your EU Regulatory Submission Stand Up to Scrutiny?

Anticipate and Respond to the Most Common Deficiencies Found by EU Notified Bodies

RQMIS can help: send an email to [email protected] for more information https://t.co/23h9D0yida

[Frank Manning @fmanning16]

Check out our latest blog on the FDA's new Total Product Lifecycle Advisory Program (TAP) Pilot

Please reach out to RQMIS at [email protected] for more details to help navigate TAP Pilot enrollment and be one of the first manufacture…https://t.co/z1iU5smr66 https://t.co/bSpyyiardo

[Frank Manning @fmanning16]

Here is our EU Blog on Medical Device Regulations for SaMD in 2023.

Please contact RQMIS to help with all your EU regulatory, clinical, and quality needs. https://t.co/UbHUhUQ0HS

[Frank Manning @fmanning16]

https://t.co/6C0Lz5GUlJ

[Frank Manning @fmanning16]

Check out our latest blog on the Evolving GCP Guidelines and Unchanging Principles in Clinical Trials.

#clinical #clinicaltrials #fda #gcp #goodclinicalpractice #ich #humansubjectprotection #RQMIS https://t.co/BjXZ1h3Hsp

[Frank Manning @fmanning16]

https://t.co/P7wrRSLxF7 https://t.co/i3bpXI5y8F

[Frank Manning @fmanning16]

https://t.co/78wKbGt8oc

[Frank Manning @fmanning16]

RQMIS is hiring for a Regulatory Affairs Associate II/III

Contact: [email protected] https://t.co/Do3DMUKLgq

[Frank Manning @fmanning16]

According to a McKinsey study, the direct cost of quality assurance in the medical device industry is USD $26 billion to USD $36 billion annually, and this will continue to grow with the market. In 2022, the medical device industry…https://t.co/ugjB8VRmD2 https://t.co/G5A5Dn0VRi

[Frank Manning @fmanning16]

BIG NEWS: RQMIS, the leader in world-class regulatory, clinical, and quality consulting in the medical device, pharmaceutical, nutraceutical, and cosmetic industries, is proud to introduce our brand new Postmarket Surveillance Serv…https://t.co/jZdGppFqZs https://t.co/QMMGBhBVUf

[Frank Manning @fmanning16]

Stay tuned tomorrow for an exciting announcement on a brand-new service from RQMIS, the leader in world-class regulatory, clinical, and quality consulting for medical device, pharmaceutical, nutraceutical, and cosmetic industries. https://t.co/veFNnYS6u7

[Frank Manning @fmanning16]

Contact RQMIS, Inc for all your Regulatory, Clinical, and Quality consulting needs.

Be sure to ask about our new Postmarket Surveillance Service. https://t.co/S5PeY7jagT

[Frank Manning @fmanning16]

Transition Plan for Devices Issues EUAs During Covid-19

Contact RQMIS to help with your Transition Plan https://t.co/irQzaNBg1B

[Frank Manning @fmanning16]

FDA ISSUES FINAL GUIDELINES for COVID-19 MEDICAL DEVICE TRANSITION PLANS

Contact RQMIS to help with your Transition Plans https://t.co/7QmCJCTBGK

[Frank Manning @fmanning16]

Attention Medical Device Manufacturers Worldwide, Linda McKeever can help with all your US Healthcare Insurance Reimbursement needs.

Please reach me at [email protected] to learn more. https://t.co/K5KkpZ8xHs

[Frank Manning @fmanning16]

RQMIS provides therapeutically focused comprehensive regulatory, quality, and clinical consulting to the global medical device, pharmaceutical, nutraceutical, and cosmetic industries

https://t.co/KmZLjC5Asz https://t.co/ClEZ2bmdj8